Search Results - Yamin Shu

Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china by Yamin Shu, Yanxin Liu, Xucheng He, Yufeng Ding, Qilin Zhang

Connect to this object online.

Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis by Wenting Zhang, Ziqi Xu, Yamin Shu, Sainan Shu, Qilin Zhang

Connect to this object online.

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system by Yamin Shu, Xucheng He, Pan Wu, Yanxin Liu, Yufeng Ding, Qilin Zhang

Connect to this object online.

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China by Yamin Shu, Yufeng Ding, Xucheng He, Yanxin Liu, Pan Wu, Qilin Zhang

Connect to this object online.

Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database by Yamin Shu, Qilin Zhang, Xucheng He, Yanxin Liu, Pan Wu, Li Chen

Connect to this object online.

Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system by Xianglin Pan, Xiangtian Xiao, Yiling Ding, Yamin Shu, Wenting Zhang, Liu Huang

Connect to this object online.

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System by Yamin Shu, Yufeng Ding, Yanxin Liu, Pan Wu, Xucheng He, Qilin Zhang

Connect to this object online.